Compare MUX & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MUX | FTRE |
|---|---|---|
| Founded | 1979 | 1996 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Medical Specialities |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 936.8M | 864.4M |
| IPO Year | N/A | N/A |
| Metric | MUX | FTRE |
|---|---|---|
| Price | $18.96 | $15.54 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 8 |
| Target Price | ★ $19.63 | $11.36 |
| AVG Volume (30 Days) | 1.0M | ★ 1.4M |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $166,453,000.00 | ★ $2,759,900,000.00 |
| Revenue This Year | $7.70 | $3.17 |
| Revenue Next Year | $29.02 | $0.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1.88 |
| 52 Week Low | $6.38 | $3.97 |
| 52 Week High | $24.88 | $20.86 |
| Indicator | MUX | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 56.56 | 72.01 |
| Support Level | $18.08 | $14.02 |
| Resistance Level | $19.73 | $16.94 |
| Average True Range (ATR) | 1.03 | 1.10 |
| MACD | 0.14 | 0.25 |
| Stochastic Oscillator | 65.20 | 77.32 |
McEwen Inc, formerly McEwen Mining Inc is a mining and minerals production and exploration company that focuses on precious and base minerals in Argentina, Mexico, and the United States. The company generates its revenue from gold and silver production. It owns and operates the wholly-owned El Gallo 1 mine in Mexico and holds a minority stake in the company that manages the San Jose mine in Argentina. More than half of the company's gold output comes from the El Gallo 1 mine, while the remaining gold production and the majority of silver production are sourced from the San Jose mine. Geographically, majority of production occurs in the United States.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.